Investigators from IRCCS San Raffaele analyzed results from a phase 1/2 study on atidarsagene autotemcel.
This content originally appeared on our sister site, HCPLive.
The gene therapy atidarsagene autotemcel (arsa-cel; Orchard Therapeutics) slowed demyelination and brain atrophy and preserved cognitive function and motor development in patients with metachromatic leukodystrophy (MLD), according to data published in The Lancet.
Atidarsagene autotemcel contains an autologous haematopoietic stem and progenitor cell (HSPC) population transduced ex vivo with a lentiviral vector encoding human arylsulfatase A (ARSA) cDNA.
Francesca Fumagalli, MD, San Raffaele Telethon Institute for Gene Therapy, IRCCS San Raffaele Scientific Institute, led an integrated analysis of results from a prospective, non-randomized, phase 1/2 clinical study and expanded-access frameworks.
Investigators treated 29 pediatric patients who had pre-symptomatic or early symptomatic early-onset MLD with biochemical and molecular confirmation of diagnosis with atidarsagene autotemscel and compared the group to an untreated natural history cohort of 31 patients with early onset metachromatic leukodystrophy, matched by age and disease subtype.
WATCH NOW: Developing Gene Therapies for Rare Diseases
An improvement of more than 10% in total gross motor function measure score at 2 years after treatment in patients who received treatment compared with controls was required to meet one of the co-primary efficacy endpoints.
A change from baseline of total peripheral blood mononuclear cell arylsulfatase A activity at 2 years after treatment compared with values before treatment was required to meet the second co-primary endpoint of the study.
When analyzed, 26 of the patients who were treated with atidarsagene autotemcel were alive with a median follow up of 3.16 years. Due to disease progression, 2 patients died, and one passed due to a sudden event that investigators deemed unlikely to be related to treatment.
The co-primary endpoints were met for both cohorts of patients including those with late-infantile MLD, as well as those with early-juvenile MLD.
Arylsulfatase A activity in peripheral blood mononuclear cells displayed a significant increase above baseline 2 years after treatment in patients with the late-infantile variant, and 5.7-fold in patients with the early-juvenile variant.
Investigators reported significant mean differences in total scores for gross motor function between treated patients and the control group for both cohorts of patients with late-infantile MLD and early-juvenile MLD when examined 2 years after treatment.
“Most treated patients progressively acquired motor skills within the predicted range of healthy children or had stabilized motor performance (maintaining the ability to walk),” investigators wrote.
The infusion was well tolerated with no evidence of abnormal clonal proliferation or replication-competent lentivirus.
“Further, most displayed normal cognitive development and prevention or delay of central and peripheral demyelination and brain atrophy throughout follow-up,” investigators stated. “Treatment benefits were particularly apparent in patients treated before symptom onset.”
At least one grade 3 adverse event, or higher, was experienced by all patients. According to investigators, most were related to conditioning or background disease. 4 patients experienced an adverse event related to atidarsagene autotemcel treatment where they developed anti-arylsulfatase A antibodies, but it didn’t affect clinical outcomes.
“Treatment with arsa-cel resulted in sustained, clinically relevant benefits in children with early-onset MLD by preserving cognitive function and motor development in most patients, and slowing demyelination and brain atrophy,” investigators concluded.
The study, “Lentiviral haematopoietic stem-cell gene therapy for early-onset metachromatic leukodystrophy: long-term results from a non-randomised, open-label phase 1/2 trial and expanded access”, was published in the The Lancet.